PMID-sentid Pub_year Sent_text compound_name comp_offset prot_official_name organism prot_offset 12970429-8 2003 Wild-type EBNA3A expression from an oriP plasmid transfected into the LCLs protected the EBNA3AHT-infected LCLs from growth arrest and death in medium without 4HT, whereas EBNA3B or EBNA3C expression was unable to protect the LCLs from growth arrest and death. 4'-hydroxytamoxifen 159-162 EBNA3A Human gammaherpesvirus 4 10-16 15004527-5 2004 MEK/PI3K and MEK/Akt-responsive cells could be maintained long-term as long as either beta-estradiol or the estrogen receptor antagonist 4-hydroxy-tamoxifen (4HT) were provided. 4'-hydroxytamoxifen 137-156 midkine Mus musculus 0-3 15004527-5 2004 MEK/PI3K and MEK/Akt-responsive cells could be maintained long-term as long as either beta-estradiol or the estrogen receptor antagonist 4-hydroxy-tamoxifen (4HT) were provided. 4'-hydroxytamoxifen 137-156 midkine Mus musculus 13-16 15004527-5 2004 MEK/PI3K and MEK/Akt-responsive cells could be maintained long-term as long as either beta-estradiol or the estrogen receptor antagonist 4-hydroxy-tamoxifen (4HT) were provided. 4'-hydroxytamoxifen 137-156 thymoma viral proto-oncogene 1 Mus musculus 17-20 15004527-5 2004 MEK/PI3K and MEK/Akt-responsive cells could be maintained long-term as long as either beta-estradiol or the estrogen receptor antagonist 4-hydroxy-tamoxifen (4HT) were provided. 4'-hydroxytamoxifen 158-161 midkine Mus musculus 0-3 15004527-5 2004 MEK/PI3K and MEK/Akt-responsive cells could be maintained long-term as long as either beta-estradiol or the estrogen receptor antagonist 4-hydroxy-tamoxifen (4HT) were provided. 4'-hydroxytamoxifen 158-161 midkine Mus musculus 13-16 15004527-5 2004 MEK/PI3K and MEK/Akt-responsive cells could be maintained long-term as long as either beta-estradiol or the estrogen receptor antagonist 4-hydroxy-tamoxifen (4HT) were provided. 4'-hydroxytamoxifen 158-161 thymoma viral proto-oncogene 1 Mus musculus 17-20 14701735-2 2004 We constructed an inducible MLL fusion, MLL-ENL-ERtm, that rendered the transcriptional and transforming properties of MLL-ENL strictly dependent on the presence of 4-hydroxy-tamoxifen. 4'-hydroxytamoxifen 165-184 lysine methyltransferase 2A Homo sapiens 28-31 14701735-2 2004 We constructed an inducible MLL fusion, MLL-ENL-ERtm, that rendered the transcriptional and transforming properties of MLL-ENL strictly dependent on the presence of 4-hydroxy-tamoxifen. 4'-hydroxytamoxifen 165-184 lysine methyltransferase 2A Homo sapiens 40-43 14701735-2 2004 We constructed an inducible MLL fusion, MLL-ENL-ERtm, that rendered the transcriptional and transforming properties of MLL-ENL strictly dependent on the presence of 4-hydroxy-tamoxifen. 4'-hydroxytamoxifen 165-184 MLLT1 super elongation complex subunit Homo sapiens 44-47 14701735-2 2004 We constructed an inducible MLL fusion, MLL-ENL-ERtm, that rendered the transcriptional and transforming properties of MLL-ENL strictly dependent on the presence of 4-hydroxy-tamoxifen. 4'-hydroxytamoxifen 165-184 lysine methyltransferase 2A Homo sapiens 40-43 14701735-2 2004 We constructed an inducible MLL fusion, MLL-ENL-ERtm, that rendered the transcriptional and transforming properties of MLL-ENL strictly dependent on the presence of 4-hydroxy-tamoxifen. 4'-hydroxytamoxifen 165-184 MLLT1 super elongation complex subunit Homo sapiens 123-126 14701735-3 2004 MLL-ENL-ERtm-immortalized hematopoietic cells required 4-hydroxy-tamoxifen for continuous growth and differentiated terminally upon tamoxifen withdrawal. 4'-hydroxytamoxifen 55-74 lysine methyltransferase 2A Homo sapiens 0-3 14701735-3 2004 MLL-ENL-ERtm-immortalized hematopoietic cells required 4-hydroxy-tamoxifen for continuous growth and differentiated terminally upon tamoxifen withdrawal. 4'-hydroxytamoxifen 55-74 MLLT1 super elongation complex subunit Homo sapiens 4-7 14652237-1 2003 BACKGROUND: Tamoxifen, a selective estrogen receptor modulator (SERM), is converted to 4-hydroxy-tamoxifen and other active metabolites by cytochrome P450 (CYP) enzymes. 4'-hydroxytamoxifen 87-106 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 139-154 14652237-1 2003 BACKGROUND: Tamoxifen, a selective estrogen receptor modulator (SERM), is converted to 4-hydroxy-tamoxifen and other active metabolites by cytochrome P450 (CYP) enzymes. 4'-hydroxytamoxifen 87-106 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 156-159 12764369-2 2003 Using DeltaMEK1:ER, a conditionally active form of MEK1 which responds to either beta-estradiol or the estrogen receptor antagonist 4 hydroxy-tamoxifen (4HT), we previously documented the ability of this dual specificity protein kinase to abrogate the cytokine-dependency of human (TF-1) and murine (FDC-P1 and FL5.12) hematopoietic cells lines. 4'-hydroxytamoxifen 153-156 mitogen-activated protein kinase kinase 1 Homo sapiens 11-15 12714703-8 2003 Trans-hydroxytamoxifen, raloxifene, and the pure antiestrogen ICI-182,780 protected against estradiol-mediated damage in breast cancer cells containing ERbeta. 4'-hydroxytamoxifen 0-22 estrogen receptor 2 Homo sapiens 152-158 12764369-4 2003 MEK1-responsive cells can be maintained long term in the presence of beta-estradiol, 4HT or IL-3. 4'-hydroxytamoxifen 85-88 mitogen-activated protein kinase kinase 1 Mus musculus 0-4 12764369-6 2003 Stimulation of DeltaMEK1:ER by 4HT resulted in ERK, PI3K, Akt and p70(S6K) activation. 4'-hydroxytamoxifen 31-34 mitogen-activated protein kinase 1 Mus musculus 47-50 12764369-6 2003 Stimulation of DeltaMEK1:ER by 4HT resulted in ERK, PI3K, Akt and p70(S6K) activation. 4'-hydroxytamoxifen 31-34 thymoma viral proto-oncogene 1 Mus musculus 58-61 12764369-6 2003 Stimulation of DeltaMEK1:ER by 4HT resulted in ERK, PI3K, Akt and p70(S6K) activation. 4'-hydroxytamoxifen 31-34 ribosomal protein S6 kinase, polypeptide 1 Mus musculus 66-69 10681578-6 2000 The antiestrogen trans-hydroxytamoxifen was a partial agonist for PI-9 mRNA induction, whereas the antiestrogen ICI 182, 780 was a pure antagonist. 4'-hydroxytamoxifen 17-39 serpin family B member 9 Homo sapiens 66-70 12554767-4 2003 Akt activation was blocked by wortmannin and LY 294,002, two inhibitors of PI 3-K; by genistein, a protein tyrosine kinase inhibitor and an ER agonist; by AG825, a selective ErbB2 inhibitor; and by the antiestrogens ICI 182,780 and 4-hydroxy-tamoxifen; but not by rapamycin, an inhibitor of the ribosomal protein kinase p70S6K; nor by AG30, a selective epidermal growth factor receptor inhibitor. 4'-hydroxytamoxifen 232-251 AKT serine/threonine kinase 1 Homo sapiens 0-3 12732288-4 2003 To study the effect of 4EM on ER-alpha and ER-beta activity, we performed transient transfection assays and showed that 4EM activated ER-dependent gene transcription in a dose-dependent manner on both ER subtypes and this activity was inhibited by trans-4-hydroxytamoxifen (4HT). 4'-hydroxytamoxifen 274-277 estrogen receptor 2 Homo sapiens 43-50 12393183-1 2002 We show here that the two antagonists ICI 182 780, a pure estrogen antagonist, and 4-hydroxy-tamoxifen, a selective estrogen receptor modulator (SERM) have distinct effects on TFF1 (formerly pS2) gene chromatin structure and transcription. 4'-hydroxytamoxifen 83-102 estrogen receptor 1 Homo sapiens 116-133 12393183-1 2002 We show here that the two antagonists ICI 182 780, a pure estrogen antagonist, and 4-hydroxy-tamoxifen, a selective estrogen receptor modulator (SERM) have distinct effects on TFF1 (formerly pS2) gene chromatin structure and transcription. 4'-hydroxytamoxifen 83-102 trefoil factor 1 Homo sapiens 176-180 12393183-1 2002 We show here that the two antagonists ICI 182 780, a pure estrogen antagonist, and 4-hydroxy-tamoxifen, a selective estrogen receptor modulator (SERM) have distinct effects on TFF1 (formerly pS2) gene chromatin structure and transcription. 4'-hydroxytamoxifen 83-102 trefoil factor 1 Homo sapiens 191-194 11821957-6 2002 Activation of Mad1 by 4-Hydroxy-Tamoxifen (OHT) resulted in abrogation of telomerase activity, reduced cloning efficiency, and decreased proportion of cells in S phase. 4'-hydroxytamoxifen 22-41 max dimerization protein 1 Rattus norvegicus 14-18 11369200-6 2001 RESULTS: The activation of c-Myc by the application of 4-hydroxy-tamoxifen caused progressive and irreversible changes in adult epidermis. 4'-hydroxytamoxifen 55-74 MYC proto-oncogene, bHLH transcription factor Homo sapiens 27-32 11369200-9 2001 The activation of c-Myc by a single application of 4-hydroxy-tamoxifen was as effective as continuous treatment in stimulating proliferation and sebocyte differentiation, and the c-Myc-induced phenotype continued to develop even after the grafting of treated skin to an untreated recipient. 4'-hydroxytamoxifen 51-70 MYC proto-oncogene, bHLH transcription factor Homo sapiens 18-23 10918503-6 2000 Upon activation of E2F1 by the ligand 4-hydroxy-tamoxifen (4-OHT) the ER-E2F1 fusion protein correctly translocated from the cytosol to the nucleus, transactivated E2F-dependent promoters, and rapidly induced substantial E2F1-related toxicity. 4'-hydroxytamoxifen 38-57 E2F transcription factor 1 Homo sapiens 19-23 10918503-6 2000 Upon activation of E2F1 by the ligand 4-hydroxy-tamoxifen (4-OHT) the ER-E2F1 fusion protein correctly translocated from the cytosol to the nucleus, transactivated E2F-dependent promoters, and rapidly induced substantial E2F1-related toxicity. 4'-hydroxytamoxifen 38-57 E2F transcription factor 1 Homo sapiens 73-77 10918503-6 2000 Upon activation of E2F1 by the ligand 4-hydroxy-tamoxifen (4-OHT) the ER-E2F1 fusion protein correctly translocated from the cytosol to the nucleus, transactivated E2F-dependent promoters, and rapidly induced substantial E2F1-related toxicity. 4'-hydroxytamoxifen 38-57 E2F transcription factor 1 Homo sapiens 73-77 12442001-3 2002 MATERIALS AND METHODS: Mice expressing Cre-ERT, a fusion between Cre-recombinase and a mutated hormone binding domain of the human estrogen receptor ERT, permit temporally and spatially controlled Cre mediated recombination in vivo by the topical application of 4-hydroxy-tamoxifen. 4'-hydroxytamoxifen 262-281 SH2 domain containing 1B2 Mus musculus 43-46 12442001-3 2002 MATERIALS AND METHODS: Mice expressing Cre-ERT, a fusion between Cre-recombinase and a mutated hormone binding domain of the human estrogen receptor ERT, permit temporally and spatially controlled Cre mediated recombination in vivo by the topical application of 4-hydroxy-tamoxifen. 4'-hydroxytamoxifen 262-281 E74 like ETS transcription factor 3 Homo sapiens 149-152 11861516-6 2002 In contrast to these BSC-pyrazoles, the antiestrogens trans-hydroxytamoxifen, raloxifene, and ICI 182,780 suppress E2 activity via both ER(alpha) and ER(beta). 4'-hydroxytamoxifen 54-76 estrogen receptor 1 Homo sapiens 136-145 11861516-6 2002 In contrast to these BSC-pyrazoles, the antiestrogens trans-hydroxytamoxifen, raloxifene, and ICI 182,780 suppress E2 activity via both ER(alpha) and ER(beta). 4'-hydroxytamoxifen 54-76 estrogen receptor 2 Homo sapiens 150-158 10536138-1 1999 Conditional DNA excision between two LoxP sites can be achieved in the mouse using Cre-ER(T), a fusion protein between a mutated ligand binding domain of the human estrogen receptor (ER) and the Cre recombinase, the activity of which can be induced by 4-hydroxy-tamoxifen (OHT), but not natural ER ligands. 4'-hydroxytamoxifen 252-271 estrogen receptor 1 Homo sapiens 164-181 10601611-7 2000 Moreover, the anti-estrogen, 4-hydroxy-tamoxifen (4OH-Tam) strongly inhibited estradiol induction of ER-beta expression, but had little or no effect on estradiol induction of ER-alpha. 4'-hydroxytamoxifen 29-48 estrogen receptor 2 Homo sapiens 101-108 10626890-2 1999 Here we constructed Stat6:ER, a Stat6-estrogen receptor fusion protein that can be activated by 4-hydroxy-tamoxifen, independently of IL-4 and endogenous Stat6. 4'-hydroxytamoxifen 96-115 signal transducer and activator of transcription 6 Homo sapiens 20-25 10626890-2 1999 Here we constructed Stat6:ER, a Stat6-estrogen receptor fusion protein that can be activated by 4-hydroxy-tamoxifen, independently of IL-4 and endogenous Stat6. 4'-hydroxytamoxifen 96-115 signal transducer and activator of transcription 6 Homo sapiens 32-37 10626890-2 1999 Here we constructed Stat6:ER, a Stat6-estrogen receptor fusion protein that can be activated by 4-hydroxy-tamoxifen, independently of IL-4 and endogenous Stat6. 4'-hydroxytamoxifen 96-115 signal transducer and activator of transcription 6 Homo sapiens 32-37 9122238-3 1997 QR is up-regulated by low concentrations of antiestrogens (trans-hydroxytamoxifen, tamoxifen, and ICI182,780) in estrogen receptor (ER)-containing breast cancer cells, and this increase is suppressed by estrogen via an ER-dependent mechanism. 4'-hydroxytamoxifen 59-81 estrogen receptor 1 Homo sapiens 113-130 10375022-6 1999 However, treatment of the ER-containing cells with estradiol or with the pure antiestrogen ICI 164 384 suppressed proliferation of the cells while the antiestrogen trans-hydroxytamoxifen had little effect on proliferation; and cotreatment with trans-hydroxytamoxifen reversed the estradiol- or ICI 164 384-evoked suppression of proliferation. 4'-hydroxytamoxifen 164-186 estrogen receptor 1 Homo sapiens 26-28 10375022-6 1999 However, treatment of the ER-containing cells with estradiol or with the pure antiestrogen ICI 164 384 suppressed proliferation of the cells while the antiestrogen trans-hydroxytamoxifen had little effect on proliferation; and cotreatment with trans-hydroxytamoxifen reversed the estradiol- or ICI 164 384-evoked suppression of proliferation. 4'-hydroxytamoxifen 244-266 estrogen receptor 1 Homo sapiens 26-28 9325313-11 1997 We show that DNA binding by ERalpha and beta are similarly affected by elevated temperature in the absence of ligand or in the presence of 17beta-estradiol and the partial estrogen agonist 4-hydroxy-tamoxifen. 4'-hydroxytamoxifen 189-208 estrogen receptor 1 Homo sapiens 28-44 9325313-12 1997 In the absence of ligand, DNA binding by ERalpha and beta is rapidly lost at 37 degrees C, while in the presence of 17beta-estradiol and 4-hydroxy-tamoxifen, the loss in DNA binding at elevated temperature is much more gradual. 4'-hydroxytamoxifen 137-156 Era like 12S mitochondrial rRNA chaperone 1 Homo sapiens 41-48 10630357-4 1999 Here we reported that paclitaxel and 4-hydroxytamoxifen (4-HT) have a synergistic cytotoxic effect on the ER-negative colon cancer cell line HCT15, which is refractory to paclitaxel alone. 4'-hydroxytamoxifen 57-61 estrogen receptor 1 Homo sapiens 106-108 10428964-7 1999 This construction (STAT3ER) induced expression of junB (one of the targets of STAT3) in ES cells in the presence of the synthetic ligand 4-hydroxytamoxifen (4HT), thereby indicating that STAT3ER is a conditionally active form. 4'-hydroxytamoxifen 157-160 jun B proto-oncogene Mus musculus 50-54 10428964-7 1999 This construction (STAT3ER) induced expression of junB (one of the targets of STAT3) in ES cells in the presence of the synthetic ligand 4-hydroxytamoxifen (4HT), thereby indicating that STAT3ER is a conditionally active form. 4'-hydroxytamoxifen 157-160 signal transducer and activator of transcription 3 Mus musculus 19-24 10428964-7 1999 This construction (STAT3ER) induced expression of junB (one of the targets of STAT3) in ES cells in the presence of the synthetic ligand 4-hydroxytamoxifen (4HT), thereby indicating that STAT3ER is a conditionally active form. 4'-hydroxytamoxifen 157-160 signal transducer and activator of transcription 3 Mus musculus 78-83 10428964-8 1999 ES cells transfected with STAT3ER cultured in the presence of 4HT maintained an undifferentiated state. 4'-hydroxytamoxifen 62-65 signal transducer and activator of transcription 3 Mus musculus 26-31 10418989-12 1999 Furthermore, the repressor could inhibit the 4-hydroxy-tamoxifen (4OH-T)-induced ER activity. 4'-hydroxytamoxifen 45-64 estrogen receptor 1 Homo sapiens 81-83 9171229-3 1997 In Hep G2 cells in which 4HT is an agonist, exogenous SRC-1 enhanced estradiol (E2)- and 4HT-stimulated transcription in a dose-dependent manner, while SMRT overexpression strongly reduced basal and 4HT-stimulated gene expression with no effect on E2 activity. 4'-hydroxytamoxifen 25-28 nuclear receptor coactivator 1 Homo sapiens 54-59 9171229-3 1997 In Hep G2 cells in which 4HT is an agonist, exogenous SRC-1 enhanced estradiol (E2)- and 4HT-stimulated transcription in a dose-dependent manner, while SMRT overexpression strongly reduced basal and 4HT-stimulated gene expression with no effect on E2 activity. 4'-hydroxytamoxifen 25-28 nuclear receptor corepressor 2 Homo sapiens 152-156 9171229-3 1997 In Hep G2 cells in which 4HT is an agonist, exogenous SRC-1 enhanced estradiol (E2)- and 4HT-stimulated transcription in a dose-dependent manner, while SMRT overexpression strongly reduced basal and 4HT-stimulated gene expression with no effect on E2 activity. 4'-hydroxytamoxifen 89-92 nuclear receptor coactivator 1 Homo sapiens 54-59 9171229-7 1997 SMRT overexpression blocked SRC-1 coactivation of 4HT-stimulated gene expression and preferentially inhibited 4HT agonist activity whether or not exogenous SRC-1 was present. 4'-hydroxytamoxifen 50-53 nuclear receptor corepressor 2 Homo sapiens 0-4 9171229-7 1997 SMRT overexpression blocked SRC-1 coactivation of 4HT-stimulated gene expression and preferentially inhibited 4HT agonist activity whether or not exogenous SRC-1 was present. 4'-hydroxytamoxifen 50-53 nuclear receptor coactivator 1 Homo sapiens 28-33 9171229-7 1997 SMRT overexpression blocked SRC-1 coactivation of 4HT-stimulated gene expression and preferentially inhibited 4HT agonist activity whether or not exogenous SRC-1 was present. 4'-hydroxytamoxifen 110-113 nuclear receptor corepressor 2 Homo sapiens 0-4 9122238-3 1997 QR is up-regulated by low concentrations of antiestrogens (trans-hydroxytamoxifen, tamoxifen, and ICI182,780) in estrogen receptor (ER)-containing breast cancer cells, and this increase is suppressed by estrogen via an ER-dependent mechanism. 4'-hydroxytamoxifen 59-81 estrogen receptor 1 Homo sapiens 132-134 7527333-3 1994 Using a semiquantitative reverse transcription-polymerase chain reaction (RT-PCR) assay, we demonstrated that both E2 and 4-hydroxy-tamoxifen (OHT) enhanced IGF-I expression but had no effect on IGF-II expression. 4'-hydroxytamoxifen 122-141 insulin like growth factor 1 Homo sapiens 157-162 8798658-2 1996 Antiestrogens, such as trans-hydroxytamoxifen (TOT), have partial agonistic activity in certain cell types, and studies have implied that this agonism is AF-1-dependent. 4'-hydroxytamoxifen 23-45 interferon gamma receptor 2 Homo sapiens 154-158 7628351-8 1995 The mutants are also powerful repressors of the agonist activity of trans-hydroxytamoxifen-stimulated ER transcription. 4'-hydroxytamoxifen 68-90 estrogen receptor 1 Homo sapiens 102-104 8816752-4 1996 We have previously shown that a ligand-dependent interaction between the two AF-containing regions of ER was promoted by E2 and the antiestrogen trans-hydroxytamoxifen (TOT). 4'-hydroxytamoxifen 145-167 estrogen receptor 1 Homo sapiens 102-104 8833652-3 1996 The ER point mutant L540Q is activated by several antiestrogens (the more pure antiestrogens ICI 164,384 and RU 54,876 or the partial antiestrogen trans-hydroxytamoxifen) but not by estradiol. 4'-hydroxytamoxifen 147-169 estrogen receptor 1 Homo sapiens 4-6 10194768-4 1999 The HeLa fER is biologically active in vivo, as judged by rapid death of the cells in the presence of either 17 beta-estradiol or trans-hydroxytamoxifen and the ability of the cell line to activate a transfected estrogen response element (ERE)-containing reporter gene. 4'-hydroxytamoxifen 130-152 FER tyrosine kinase Homo sapiens 9-12 1997187-3 1991 Inhibition with trans-hydroxytamoxifen was IL-1 alpha dose dependent (maximum = 97% at 1000 units/ml, P less than 0.01) and estradiol dose dependent (reversible with 10(-8) M estradiol, maximum inhibition at 10(-10) M estradiol). 4'-hydroxytamoxifen 16-38 interleukin 1 alpha Homo sapiens 43-53 8344199-1 1993 In MCF7 human breast cancer cells, the antiestrogens 4-hydroxy-tamoxifen and ICI 164,384 inhibit the mitogenic activity of epidermal growth factor (EGF) and insulin-like growth factor-I (IGF-I). 4'-hydroxytamoxifen 53-72 insulin like growth factor 1 Homo sapiens 157-185 8344199-1 1993 In MCF7 human breast cancer cells, the antiestrogens 4-hydroxy-tamoxifen and ICI 164,384 inhibit the mitogenic activity of epidermal growth factor (EGF) and insulin-like growth factor-I (IGF-I). 4'-hydroxytamoxifen 53-72 insulin like growth factor 1 Homo sapiens 187-192 1406642-3 1992 The ER is capable of binding to the promoter interference constructs in the absence of added ligand, and estrogen (estradiol) or antiestrogen (trans-hydroxytamoxifen or ICI 164,384) enhances or stabilizes this interaction. 4'-hydroxytamoxifen 143-165 estrogen receptor 1 Homo sapiens 4-6 10194768-10 1999 At high levels of transfected HMG-1 expression plasmid, transactivation by ER became partially ligand-independent, and transactivation by trans-hydroxytamoxifen was increased by more than 25-fold. 4'-hydroxytamoxifen 138-160 high mobility group box 1 pseudogene 5 Homo sapiens 30-35 30614492-4 2018 We demonstrate the differential 4-hydroxy-tamoxifen (4OHT) effect on mouse and human ERalpha ligand-binding domain (LBD) dimerization activity using the mammalian two-hybrid (M2H) assay. 4'-hydroxytamoxifen 32-51 estrogen receptor 1 Homo sapiens 85-92 6704137-1 1984 Tamoxifen (Nolvadex; TAM) and its major metabolites, N-desmethyl- (DMT) and 4-hydroxy-tamoxifen (HT), were shown to be potent inhibitors of hepatic cytochrome P-450-dependent mixed function oxidations. 4'-hydroxytamoxifen 76-95 cytochrome P450, family 2, subfamily g, polypeptide 1 Rattus norvegicus 148-164 121266-2 1979 One of the major metabolites is 4-hydroxy-tamoxifen which we have identified by cocrystallisation withe non radioactive compound and which is known to display a high affinity for the estrogen receptor. 4'-hydroxytamoxifen 32-51 estrogen receptor 1 Rattus norvegicus 183-200 28892037-6 2017 At postnatal day 1 (P1), we used 4-hydroxytamoxifen (4HT) to activate Cre recombinase activity from the Cdh5-CreErt2 transgene to cleave the floxed allele of Ccm2. 4'-hydroxytamoxifen 53-56 cadherin 5 Mus musculus 104-108 29980405-6 2018 Likewise, the sensitivity to drugs used to treat other cancers such as: doxorubicin, mitoxantrone, and 4 hydroxy tamoxifen (4HT) also increased upon introduction of WT-TP53 into MIA-PaCa-2 cells. 4'-hydroxytamoxifen 124-127 tumor protein p53 Homo sapiens 168-172 29589904-3 2018 We show that when an analogue-sensitive ZAP70 allele is fused to the engineered ligand binding domain of the estrogen receptor, ERT2, its activity can be upregulated to an extent by a metabolite of an FDA-approved tamoxifen, 4-hydroxy-tamoxifen, and downregulated by an ATP analogue, 3-MB-PP1. 4'-hydroxytamoxifen 225-244 zeta chain of T cell receptor associated protein kinase 70 Homo sapiens 40-45 29589904-3 2018 We show that when an analogue-sensitive ZAP70 allele is fused to the engineered ligand binding domain of the estrogen receptor, ERT2, its activity can be upregulated to an extent by a metabolite of an FDA-approved tamoxifen, 4-hydroxy-tamoxifen, and downregulated by an ATP analogue, 3-MB-PP1. 4'-hydroxytamoxifen 225-244 mitogen-activated protein kinase 3 Homo sapiens 128-132 28849250-7 2017 RESULTS: CYP3A4*22 carriers reached significant higher concentrations of tamoxifen, N-desmethyl-tamoxifen, and 4-hydroxy-tamoxifen compared to non-carriers, whereas a tendency toward increased endoxifen levels was observed (p = 0.088). 4'-hydroxytamoxifen 111-130 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 9-15 28849250-10 2017 CYP3A5*3 marginally improved the explained variability of the (log transformed) metabolic ratio 4-hydroxy-tamoxifen/endoxifen (from 44.9 to 46.2%, p < 0.038). 4'-hydroxytamoxifen 96-115 cytochrome P450 family 3 subfamily A member 5 Homo sapiens 0-6 30120701-7 2018 RESULTS: In the low SULT1A1 activity group, higher endoxifen and 4-hydroxy-tamoxifen concentrations were found, compared to the medium and high activity group (endoxifen: 31.23 vs. 30.51 vs. 27.00, p value: 0.016; 4-hydroxy-tamoxifen: 5.55 vs. 5.27 vs. 4.94, p value:0.05). 4'-hydroxytamoxifen 65-84 sulfotransferase family 1A member 1 Homo sapiens 20-27 30120701-7 2018 RESULTS: In the low SULT1A1 activity group, higher endoxifen and 4-hydroxy-tamoxifen concentrations were found, compared to the medium and high activity group (endoxifen: 31.23 vs. 30.51 vs. 27.00, p value: 0.016; 4-hydroxy-tamoxifen: 5.55 vs. 5.27 vs. 4.94, p value:0.05). 4'-hydroxytamoxifen 214-233 sulfotransferase family 1A member 1 Homo sapiens 20-27 28993021-7 2018 They were induced upon exposure to various progestins and corticosteroids and could be recovered using the progesterone receptor/glucocorticoid receptor antagonist mifepristone; this, however, was not the case for estrogens and the estrogen receptor antagonist 4-hydroxy-tamoxifen. 4'-hydroxytamoxifen 261-280 progesterone receptor Danio rerio 107-128 28892037-6 2017 At postnatal day 1 (P1), we used 4-hydroxytamoxifen (4HT) to activate Cre recombinase activity from the Cdh5-CreErt2 transgene to cleave the floxed allele of Ccm2. 4'-hydroxytamoxifen 53-56 cerebral cavernous malformation 2 Mus musculus 158-162 28273169-4 2017 We found that the catalytic activity of the SIRT1-ER fusion protein increased 4-5 fold in cells treated with its ligand, 4-hydroxy-tamoxifen (4OHT). 4'-hydroxytamoxifen 121-140 sirtuin 1 Mus musculus 44-49 27991921-1 2017 To study ROCK2 activation in carcinogenesis, mice expressing 4-hydroxytamoxifen (4HT)-activated ROCK2 (K14.ROCKer) were crossed with mice expressing epidermal-activated rasHa (HK1.ras1205). 4'-hydroxytamoxifen 81-84 Rho-associated coiled-coil containing protein kinase 2 Mus musculus 96-101 27991921-2 2017 At 8 weeks, 4HT-treated K14.ROCKer/HK1.ras1205 cohorts exhibited papillomas similar to HK1.ras1205 controls; however, K14.ROCKer/HK1.ras1205 histotypes comprised a mixed papilloma/well-differentiated squamous cell carcinoma (wdSCC), exhibiting p53 loss, increased proliferation and novel NF-kappaB expression. 4'-hydroxytamoxifen 12-15 transformation related protein 53, pseudogene Mus musculus 244-247 27991921-2 2017 At 8 weeks, 4HT-treated K14.ROCKer/HK1.ras1205 cohorts exhibited papillomas similar to HK1.ras1205 controls; however, K14.ROCKer/HK1.ras1205 histotypes comprised a mixed papilloma/well-differentiated squamous cell carcinoma (wdSCC), exhibiting p53 loss, increased proliferation and novel NF-kappaB expression. 4'-hydroxytamoxifen 12-15 nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105 Mus musculus 288-297 27991921-5 2017 Malignancy depended on ROCKer/p-Mypt1 expression, as cessation of 4HT treatment induced disorganized tissue architecture and p21-associated differentiation in wdSCCs; yet tenascin C retention in connective tissue extracellular matrix suggests the rigidity laid down for conversion persists. 4'-hydroxytamoxifen 66-69 protein phosphatase 1, regulatory subunit 12A Mus musculus 32-37 27991921-5 2017 Malignancy depended on ROCKer/p-Mypt1 expression, as cessation of 4HT treatment induced disorganized tissue architecture and p21-associated differentiation in wdSCCs; yet tenascin C retention in connective tissue extracellular matrix suggests the rigidity laid down for conversion persists. 4'-hydroxytamoxifen 66-69 cyclin-dependent kinase inhibitor 1A (P21) Mus musculus 125-128 29599800-5 2017 Estrogen receptor- (ER-) positive T47D breast cancer cells are less sensitive to 4-hydroxytamoxifen (4-HT) treatment when cultured on the 3D porous scaffolds than in 2D cultures. 4'-hydroxytamoxifen 101-105 estrogen receptor 1 Homo sapiens 0-17 26691151-5 2016 ERE-WT cells displayed a biphasic transcriptional response after TNFalpha treatment, the acute phase of which was blocked after treatment with the estrogen receptor antagonist 4-hydroxy-tamoxifen. 4'-hydroxytamoxifen 176-195 tumor necrosis factor Homo sapiens 65-73 25940823-3 2015 Tamoxifen is bioactivated by cytochrome P450 (CYP) enzymes such as CYP2B6, CYP2C9, CYP2C19, CYP2D6 and CYP3A4/5, resulting in the formation of active metabolites, including 4-hydroxy-tamoxifen and endoxifen. 4'-hydroxytamoxifen 173-192 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 29-44 25940823-3 2015 Tamoxifen is bioactivated by cytochrome P450 (CYP) enzymes such as CYP2B6, CYP2C9, CYP2C19, CYP2D6 and CYP3A4/5, resulting in the formation of active metabolites, including 4-hydroxy-tamoxifen and endoxifen. 4'-hydroxytamoxifen 173-192 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 46-49 25940823-3 2015 Tamoxifen is bioactivated by cytochrome P450 (CYP) enzymes such as CYP2B6, CYP2C9, CYP2C19, CYP2D6 and CYP3A4/5, resulting in the formation of active metabolites, including 4-hydroxy-tamoxifen and endoxifen. 4'-hydroxytamoxifen 173-192 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 67-73 25940823-3 2015 Tamoxifen is bioactivated by cytochrome P450 (CYP) enzymes such as CYP2B6, CYP2C9, CYP2C19, CYP2D6 and CYP3A4/5, resulting in the formation of active metabolites, including 4-hydroxy-tamoxifen and endoxifen. 4'-hydroxytamoxifen 173-192 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 75-81 25940823-3 2015 Tamoxifen is bioactivated by cytochrome P450 (CYP) enzymes such as CYP2B6, CYP2C9, CYP2C19, CYP2D6 and CYP3A4/5, resulting in the formation of active metabolites, including 4-hydroxy-tamoxifen and endoxifen. 4'-hydroxytamoxifen 173-192 cytochrome P450 family 2 subfamily C member 19 Homo sapiens 83-90 25940823-3 2015 Tamoxifen is bioactivated by cytochrome P450 (CYP) enzymes such as CYP2B6, CYP2C9, CYP2C19, CYP2D6 and CYP3A4/5, resulting in the formation of active metabolites, including 4-hydroxy-tamoxifen and endoxifen. 4'-hydroxytamoxifen 173-192 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 92-98 25940823-3 2015 Tamoxifen is bioactivated by cytochrome P450 (CYP) enzymes such as CYP2B6, CYP2C9, CYP2C19, CYP2D6 and CYP3A4/5, resulting in the formation of active metabolites, including 4-hydroxy-tamoxifen and endoxifen. 4'-hydroxytamoxifen 173-192 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 103-109 25610726-3 2014 Here, we characterized the chemotherapeutic response of melanomas caused by 4-hydroxy-tamoxifen-induced expression of the Cre recombinase in melanocytes that results in the activation of oncogenic Braf together with the inactivation of the tumor suppressor Pten, as well as the optional inactivation of the essential autophagy gene Atg7. 4'-hydroxytamoxifen 76-95 B-Raf proto-oncogene, serine/threonine kinase Homo sapiens 197-201 25064027-1 2014 BACKGROUND: Because oestrogen receptor alpha (ERalpha) regulates E2F1 expression to mediate tamoxifen resistance in ERalpha-positive breast cancer cells, we aimed to define the possible roles of ERalpha and E2F1 in promoting the resistance of ERalpha-negative breast cancer cells to 4-hydroxy-tamoxifen (4OHT). 4'-hydroxytamoxifen 283-302 estrogen receptor 1 Homo sapiens 46-53 25610726-3 2014 Here, we characterized the chemotherapeutic response of melanomas caused by 4-hydroxy-tamoxifen-induced expression of the Cre recombinase in melanocytes that results in the activation of oncogenic Braf together with the inactivation of the tumor suppressor Pten, as well as the optional inactivation of the essential autophagy gene Atg7. 4'-hydroxytamoxifen 76-95 phosphatase and tensin homolog Homo sapiens 257-261 25610726-3 2014 Here, we characterized the chemotherapeutic response of melanomas caused by 4-hydroxy-tamoxifen-induced expression of the Cre recombinase in melanocytes that results in the activation of oncogenic Braf together with the inactivation of the tumor suppressor Pten, as well as the optional inactivation of the essential autophagy gene Atg7. 4'-hydroxytamoxifen 76-95 autophagy related 7 Homo sapiens 332-336 24156637-1 2013 BACKGROUND: 4-Hydroxy-tamoxifen (4OHT) triggers Cre-mediated K-Ras removal in [H-Ras-/-; N-Ras-/-; K-Ras lox/lox; RERT ert/ert] fibroblasts, generating growth-arrested "Rasless" MEFs which are able to recover their proliferative ability after ectopic expression of Ras oncoproteins or constitutively active BRAF or MEK1. 4'-hydroxytamoxifen 12-31 KRAS proto-oncogene, GTPase Homo sapiens 61-66 24177192-2 2013 To investigate the molecular mechanisms by which HoxA9 promotes immortalization of hematopoietic cells, we generated growth factor dependent myeloid cells in which HoxA9 expression is regulated by administration of 4-hydroxy-tamoxifen. 4'-hydroxytamoxifen 215-234 homeobox A9 Homo sapiens 49-54 24177192-2 2013 To investigate the molecular mechanisms by which HoxA9 promotes immortalization of hematopoietic cells, we generated growth factor dependent myeloid cells in which HoxA9 expression is regulated by administration of 4-hydroxy-tamoxifen. 4'-hydroxytamoxifen 215-234 homeobox A9 Homo sapiens 164-169 24156637-1 2013 BACKGROUND: 4-Hydroxy-tamoxifen (4OHT) triggers Cre-mediated K-Ras removal in [H-Ras-/-; N-Ras-/-; K-Ras lox/lox; RERT ert/ert] fibroblasts, generating growth-arrested "Rasless" MEFs which are able to recover their proliferative ability after ectopic expression of Ras oncoproteins or constitutively active BRAF or MEK1. 4'-hydroxytamoxifen 12-31 lysyl oxidase Homo sapiens 105-108 24156637-1 2013 BACKGROUND: 4-Hydroxy-tamoxifen (4OHT) triggers Cre-mediated K-Ras removal in [H-Ras-/-; N-Ras-/-; K-Ras lox/lox; RERT ert/ert] fibroblasts, generating growth-arrested "Rasless" MEFs which are able to recover their proliferative ability after ectopic expression of Ras oncoproteins or constitutively active BRAF or MEK1. 4'-hydroxytamoxifen 12-31 lysyl oxidase Homo sapiens 109-112 24156637-1 2013 BACKGROUND: 4-Hydroxy-tamoxifen (4OHT) triggers Cre-mediated K-Ras removal in [H-Ras-/-; N-Ras-/-; K-Ras lox/lox; RERT ert/ert] fibroblasts, generating growth-arrested "Rasless" MEFs which are able to recover their proliferative ability after ectopic expression of Ras oncoproteins or constitutively active BRAF or MEK1. 4'-hydroxytamoxifen 12-31 E74 like ETS transcription factor 3 Homo sapiens 119-122 24156637-1 2013 BACKGROUND: 4-Hydroxy-tamoxifen (4OHT) triggers Cre-mediated K-Ras removal in [H-Ras-/-; N-Ras-/-; K-Ras lox/lox; RERT ert/ert] fibroblasts, generating growth-arrested "Rasless" MEFs which are able to recover their proliferative ability after ectopic expression of Ras oncoproteins or constitutively active BRAF or MEK1. 4'-hydroxytamoxifen 12-31 E74 like ETS transcription factor 3 Homo sapiens 123-126 24156637-1 2013 BACKGROUND: 4-Hydroxy-tamoxifen (4OHT) triggers Cre-mediated K-Ras removal in [H-Ras-/-; N-Ras-/-; K-Ras lox/lox; RERT ert/ert] fibroblasts, generating growth-arrested "Rasless" MEFs which are able to recover their proliferative ability after ectopic expression of Ras oncoproteins or constitutively active BRAF or MEK1. 4'-hydroxytamoxifen 12-31 B-Raf proto-oncogene, serine/threonine kinase Homo sapiens 307-311 24156637-1 2013 BACKGROUND: 4-Hydroxy-tamoxifen (4OHT) triggers Cre-mediated K-Ras removal in [H-Ras-/-; N-Ras-/-; K-Ras lox/lox; RERT ert/ert] fibroblasts, generating growth-arrested "Rasless" MEFs which are able to recover their proliferative ability after ectopic expression of Ras oncoproteins or constitutively active BRAF or MEK1. 4'-hydroxytamoxifen 12-31 mitogen-activated protein kinase kinase 1 Homo sapiens 315-319 24156637-1 2013 BACKGROUND: 4-Hydroxy-tamoxifen (4OHT) triggers Cre-mediated K-Ras removal in [H-Ras-/-; N-Ras-/-; K-Ras lox/lox; RERT ert/ert] fibroblasts, generating growth-arrested "Rasless" MEFs which are able to recover their proliferative ability after ectopic expression of Ras oncoproteins or constitutively active BRAF or MEK1. 4'-hydroxytamoxifen 12-31 HRas proto-oncogene, GTPase Homo sapiens 79-84 24156637-1 2013 BACKGROUND: 4-Hydroxy-tamoxifen (4OHT) triggers Cre-mediated K-Ras removal in [H-Ras-/-; N-Ras-/-; K-Ras lox/lox; RERT ert/ert] fibroblasts, generating growth-arrested "Rasless" MEFs which are able to recover their proliferative ability after ectopic expression of Ras oncoproteins or constitutively active BRAF or MEK1. 4'-hydroxytamoxifen 12-31 NRAS proto-oncogene, GTPase Homo sapiens 89-94 24156637-1 2013 BACKGROUND: 4-Hydroxy-tamoxifen (4OHT) triggers Cre-mediated K-Ras removal in [H-Ras-/-; N-Ras-/-; K-Ras lox/lox; RERT ert/ert] fibroblasts, generating growth-arrested "Rasless" MEFs which are able to recover their proliferative ability after ectopic expression of Ras oncoproteins or constitutively active BRAF or MEK1. 4'-hydroxytamoxifen 12-31 KRAS proto-oncogene, GTPase Homo sapiens 99-104 23951246-7 2013 Although GPER was found to be specifically induced by LH/FSH, GPER agonists (4-Hydroxy-Tamoxifen, G1) reduced EOC cell proliferation only in case of LH/FSH unstimulated pathways. 4'-hydroxytamoxifen 77-96 G protein-coupled estrogen receptor 1 Homo sapiens 62-66 24040083-9 2013 Importantly, by using a p53ER (TAM) knockin model expressing a variant of p53 that is completely dependent on 4-hydroxy-tamoxifen for its activity, we show that p53 activation diminished SALL2 RNA and protein levels during genotoxic cellular stress in primary mouse embryo fibroblasts (MEFs) and radiosensitive tissues in vivo. 4'-hydroxytamoxifen 110-129 transformation related protein 53, pseudogene Mus musculus 24-27 24040083-9 2013 Importantly, by using a p53ER (TAM) knockin model expressing a variant of p53 that is completely dependent on 4-hydroxy-tamoxifen for its activity, we show that p53 activation diminished SALL2 RNA and protein levels during genotoxic cellular stress in primary mouse embryo fibroblasts (MEFs) and radiosensitive tissues in vivo. 4'-hydroxytamoxifen 110-129 transformation related protein 53, pseudogene Mus musculus 74-77 24040083-9 2013 Importantly, by using a p53ER (TAM) knockin model expressing a variant of p53 that is completely dependent on 4-hydroxy-tamoxifen for its activity, we show that p53 activation diminished SALL2 RNA and protein levels during genotoxic cellular stress in primary mouse embryo fibroblasts (MEFs) and radiosensitive tissues in vivo. 4'-hydroxytamoxifen 110-129 spalt like transcription factor 2 Mus musculus 187-192 23752064-3 2013 Subsequent treatment with 4-hydroxy-tamoxifen (4-OHT) induced ER-beta nuclear translocation, upregulated pS2 and p21 levels and reduced cell viability. 4'-hydroxytamoxifen 26-45 estrogen receptor 2 Homo sapiens 62-69 23752064-3 2013 Subsequent treatment with 4-hydroxy-tamoxifen (4-OHT) induced ER-beta nuclear translocation, upregulated pS2 and p21 levels and reduced cell viability. 4'-hydroxytamoxifen 26-45 taste 2 receptor member 64 pseudogene Homo sapiens 105-108 23752064-3 2013 Subsequent treatment with 4-hydroxy-tamoxifen (4-OHT) induced ER-beta nuclear translocation, upregulated pS2 and p21 levels and reduced cell viability. 4'-hydroxytamoxifen 26-45 H3 histone pseudogene 16 Homo sapiens 113-116 23574448-11 2013 The transcript levels of genes coding for catalase, premelanosome protein and melan-A, directly related to skin and hair pigmentation, showed an increased tendency upon tamoxifen and 4-hydroxy-tamoxifen treatment. 4'-hydroxytamoxifen 183-202 catalase Homo sapiens 42-50 22020327-2 2012 Activation of the GFP-RAF1-ER kinase by addition of 4-hydroxy-tamoxifen led to a robust induction of senescence within one population doubling, accompanied by the assembly of heterochromatic foci. 4'-hydroxytamoxifen 52-71 Raf-1 proto-oncogene, serine/threonine kinase Homo sapiens 22-26 22710719-7 2013 Using K562 sublines with conditional MYC expression (induced by Zn(2+) or activated by 4-hydroxy-tamoxifen) we show that MYC prevented the erythroid differentiation induced by imatinib and dasatinib. 4'-hydroxytamoxifen 87-106 MYC proto-oncogene, bHLH transcription factor Homo sapiens 121-124 23014840-11 2012 The decrease in ERalpha mobility with E(2) or the selective ER modulator 4-hydroxyl-tamoxifen (4HT) was largely due to the interaction of the receptor with ERE. 4'-hydroxytamoxifen 95-98 estrogen receptor 1 Homo sapiens 16-23 22677141-0 2012 Conformational dynamics of CYP3A4 demonstrate the important role of Arg212 coupled with the opening of ingress, egress and solvent channels to dehydrogenation of 4-hydroxy-tamoxifen. 4'-hydroxytamoxifen 162-181 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 27-33 22677141-4 2012 4-Hydroxy-tamoxifen (4OHT) is metabolized by CYP3A4 via competing hydroxylation and dehydrogenation reactions. 4'-hydroxytamoxifen 0-19 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 45-51 23922954-8 2013 Patients featuring the SULT1A2*2 and SULT1A2*3 alleles showed significantly higher plasma levels of 4-hydroxy-tamoxifen and endoxifen (p = 0.025 and p = 0.006, respectively), as likely substrates of the SULT1A2 enzyme. 4'-hydroxytamoxifen 100-119 sulfotransferase family 1A member 2 Homo sapiens 23-30 23922954-8 2013 Patients featuring the SULT1A2*2 and SULT1A2*3 alleles showed significantly higher plasma levels of 4-hydroxy-tamoxifen and endoxifen (p = 0.025 and p = 0.006, respectively), as likely substrates of the SULT1A2 enzyme. 4'-hydroxytamoxifen 100-119 sulfotransferase family 1A member 2 Homo sapiens 37-44 23922954-8 2013 Patients featuring the SULT1A2*2 and SULT1A2*3 alleles showed significantly higher plasma levels of 4-hydroxy-tamoxifen and endoxifen (p = 0.025 and p = 0.006, respectively), as likely substrates of the SULT1A2 enzyme. 4'-hydroxytamoxifen 100-119 sulfotransferase family 1A member 2 Homo sapiens 37-44 23922954-9 2013 Our observations indicate that besides the CYP2D6 genotype leading to tamoxifen conversion to potent hydroxylated metabolites in a manner consistent with a gene-dose effect, SULT1A2 also seems to play a role in maintaining optimal levels of both 4-hydroxy-tamoxifen and endoxifen. 4'-hydroxytamoxifen 246-265 sulfotransferase family 1A member 2 Homo sapiens 174-181 22523547-6 2012 To specifically address whether SRY contributes to WDR5 regulation, we introduced a 4-hydroxy-tamoxifen-inducible SRY allele into LNCaP cells. 4'-hydroxytamoxifen 84-103 sex determining region Y Homo sapiens 114-117 22425775-6 2012 Moreover, GPR30 boosts HRG-beta1-induced migration and invasion of SkBr3 cells after combinative treatment with E2, 4-hydroxy-tamoxifen or the specific GPR30 agonist G-1, which are blocked by the specific GPR30 antagonist G-15 or the transfection with the small interfering RNA for GPR30. 4'-hydroxytamoxifen 116-135 G protein-coupled estrogen receptor 1 Homo sapiens 10-15 22708928-1 2012 BACKGROUND: Sulfotransferase 1A1 (SULT1A1) participates in the elimination of 4-hydroxy-tamoxifen (4-OH-TAM), which is one of the major active metabolites of tamoxifen (TAM). 4'-hydroxytamoxifen 78-97 sulfotransferase family 1A member 1 Homo sapiens 12-32 22708928-1 2012 BACKGROUND: Sulfotransferase 1A1 (SULT1A1) participates in the elimination of 4-hydroxy-tamoxifen (4-OH-TAM), which is one of the major active metabolites of tamoxifen (TAM). 4'-hydroxytamoxifen 78-97 sulfotransferase family 1A member 1 Homo sapiens 34-41 21730367-4 2011 MCF-7 cells which expressed a constitutively-activated Akt-1 gene [ Akt-1(CA)] were more resistant to doxorubicin, etoposide and 4-OH-tamoxifen (4HT) than cells lacking Akt-1(CA). 4'-hydroxytamoxifen 145-148 AKT serine/threonine kinase 1 Homo sapiens 68-73 21402720-3 2011 This study addressed the possible advantage of selenocysteine (Sec) vs. Cys in the essential selenoprotein glutathione peroxidase 4 (GPx4), using 4-hydroxy-tamoxifen-inducible Cre-excision of loxP-flanked GPx4 alleles in murine cells. 4'-hydroxytamoxifen 146-165 glutathione peroxidase 4 Mus musculus 133-137 21730367-4 2011 MCF-7 cells which expressed a constitutively-activated Akt-1 gene [ Akt-1(CA)] were more resistant to doxorubicin, etoposide and 4-OH-tamoxifen (4HT) than cells lacking Akt-1(CA). 4'-hydroxytamoxifen 145-148 AKT serine/threonine kinase 1 Homo sapiens 55-60 21321982-0 2011 Androgen receptor and heterogeneous nuclear ribonucleoprotein K colocalize in the nucleoplasm and are modulated by bicalutamide and 4-hydroxy-tamoxifen in prostatic cancer cell lines. 4'-hydroxytamoxifen 132-151 androgen receptor Homo sapiens 0-17 21321982-0 2011 Androgen receptor and heterogeneous nuclear ribonucleoprotein K colocalize in the nucleoplasm and are modulated by bicalutamide and 4-hydroxy-tamoxifen in prostatic cancer cell lines. 4'-hydroxytamoxifen 132-151 heterogeneous nuclear ribonucleoprotein K Homo sapiens 22-63 21744342-5 2011 Here we establish an inducible oncogenic zebrafish cell model, in which oncogenic human Raf-1(DeltaRaf1) can be post-transcriptionally activated in zebrafish liver cells by administration of 4-hydroxytamoxifen (4HT). 4'-hydroxytamoxifen 211-214 Raf-1 proto-oncogene, serine/threonine kinase Homo sapiens 88-103 21852537-5 2011 In place of wild-type p53, p53ER(TAM) knockin mice express a variant of p53, p53ER(TAM), that is completely dependent on 4-hydroxy-tamoxifen for its activity. 4'-hydroxytamoxifen 121-140 transformation related protein 53, pseudogene Mus musculus 27-30 21852537-5 2011 In place of wild-type p53, p53ER(TAM) knockin mice express a variant of p53, p53ER(TAM), that is completely dependent on 4-hydroxy-tamoxifen for its activity. 4'-hydroxytamoxifen 121-140 transformation related protein 53, pseudogene Mus musculus 27-30 21852537-5 2011 In place of wild-type p53, p53ER(TAM) knockin mice express a variant of p53, p53ER(TAM), that is completely dependent on 4-hydroxy-tamoxifen for its activity. 4'-hydroxytamoxifen 121-140 transformation related protein 53, pseudogene Mus musculus 27-30 21727187-3 2011 We generated a conditional zebrafish model of T-ALL in which 4-hydroxytamoxifen (4HT) treatment induces MYC activation and disease, and withdrawal of 4HT results in T-ALL apoptosis and tumor regression. 4'-hydroxytamoxifen 81-84 MYC proto-oncogene, bHLH transcription factor a Danio rerio 104-107 21730367-4 2011 MCF-7 cells which expressed a constitutively-activated Akt-1 gene [ Akt-1(CA)] were more resistant to doxorubicin, etoposide and 4-OH-tamoxifen (4HT) than cells lacking Akt-1(CA). 4'-hydroxytamoxifen 145-148 AKT serine/threonine kinase 1 Homo sapiens 68-77 21730367-4 2011 MCF-7 cells which expressed a constitutively-activated Akt-1 gene [ Akt-1(CA)] were more resistant to doxorubicin, etoposide and 4-OH-tamoxifen (4HT) than cells lacking Akt-1(CA). 4'-hydroxytamoxifen 145-148 AKT serine/threonine kinase 1 Homo sapiens 74-76 21730367-6 2011 Furthermore, rapamycin lowered the IC50s for doxorubicin, etoposide and 4HT in the cells which expressed Akt-1(CA), demonstrating a potential improved method for treating certain breast cancers which have deregulated PI3K/PTEN/Akt/mTOR signaling. 4'-hydroxytamoxifen 72-75 AKT serine/threonine kinase 1 Homo sapiens 106-111 21730367-6 2011 Furthermore, rapamycin lowered the IC50s for doxorubicin, etoposide and 4HT in the cells which expressed Akt-1(CA), demonstrating a potential improved method for treating certain breast cancers which have deregulated PI3K/PTEN/Akt/mTOR signaling. 4'-hydroxytamoxifen 72-75 AKT serine/threonine kinase 1 Homo sapiens 112-114 21730367-6 2011 Furthermore, rapamycin lowered the IC50s for doxorubicin, etoposide and 4HT in the cells which expressed Akt-1(CA), demonstrating a potential improved method for treating certain breast cancers which have deregulated PI3K/PTEN/Akt/mTOR signaling. 4'-hydroxytamoxifen 72-75 AKT serine/threonine kinase 1 Homo sapiens 106-109 20016782-6 2009 By using two independent Cre-dependent reporters in cultured cells, the combination of NCre-ERT2+ERT2-CCre was identified as having the most favorable properties of all constructs tested, showing an induction ratio of about 10 and EC(50)-values for 4-hydroxy-tamoxifen of 10 nM to 70 nM. 4'-hydroxytamoxifen 249-268 mitogen-activated protein kinase 3 Mus musculus 92-96 21086978-1 2010 Tamoxifen (Tam), the antiestrogen used to treat estrogen receptor-positive breast cancer is a pro-drug that is converted to its major active metabolites, endoxifen and 4-hydroxy-tamoxifen (4-OH-Tam) by various biotransformation enzymes of which cytochrome P450-2D6 (CYP2D6) is key. 4'-hydroxytamoxifen 168-187 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 245-264 21086978-1 2010 Tamoxifen (Tam), the antiestrogen used to treat estrogen receptor-positive breast cancer is a pro-drug that is converted to its major active metabolites, endoxifen and 4-hydroxy-tamoxifen (4-OH-Tam) by various biotransformation enzymes of which cytochrome P450-2D6 (CYP2D6) is key. 4'-hydroxytamoxifen 168-187 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 266-272 20549698-5 2011 We show that p53 mutated cells were more resistant to cytotoxic effects of 4-hydroxy-tamoxifen (OHT) compared to p53 wild-type cells. 4'-hydroxytamoxifen 75-94 tumor protein p53 Homo sapiens 13-16 19655245-5 2010 We also found that higher-expressing ENO-1 tumors confer longer distance relapse (tumor/normal ratio = 82.8-92.4-fold) when compared to locoregional relapse (tumor/normal ratio = 43.4-fold) in postsurgical 4-hydroxy-tamoxifen (4-OHT)-treated ER+ patients (*P = .014). 4'-hydroxytamoxifen 206-225 enolase 1 Homo sapiens 37-42 20016782-6 2009 By using two independent Cre-dependent reporters in cultured cells, the combination of NCre-ERT2+ERT2-CCre was identified as having the most favorable properties of all constructs tested, showing an induction ratio of about 10 and EC(50)-values for 4-hydroxy-tamoxifen of 10 nM to 70 nM. 4'-hydroxytamoxifen 249-268 mitogen-activated protein kinase 3 Mus musculus 97-101 19211844-3 2009 To specifically address whether FKHRL1 contributes to Survivin regulation, we introduced a 4-hydroxy-tamoxifen-regulated FKHRL1(A3)ERtm allele into NB cells. 4'-hydroxytamoxifen 91-110 forkhead box O3 Homo sapiens 121-127 19391117-2 2009 We generated mice expressing 4-hydroxytamoxifen (4HT)-regulated human ROCK II (ROCKII:mER) under the transcriptional control of the cytokeratin14 (K14) promoter. 4'-hydroxytamoxifen 49-52 Rho associated coiled-coil containing protein kinase 2 Homo sapiens 70-77 19391117-2 2009 We generated mice expressing 4-hydroxytamoxifen (4HT)-regulated human ROCK II (ROCKII:mER) under the transcriptional control of the cytokeratin14 (K14) promoter. 4'-hydroxytamoxifen 49-52 keratin 14 Homo sapiens 132-145 19391117-2 2009 We generated mice expressing 4-hydroxytamoxifen (4HT)-regulated human ROCK II (ROCKII:mER) under the transcriptional control of the cytokeratin14 (K14) promoter. 4'-hydroxytamoxifen 49-52 keratin 14 Homo sapiens 147-150 17159137-5 2006 WT EBNA3C expression from an oriP plasmid transfected into E3C-HT LCLs protected the LCLs from growth arrest in medium without 4HT, whereas expression of EBNA3A or EBNA3B did not. 4'-hydroxytamoxifen 127-130 EBNA-3C Human gammaherpesvirus 4 3-9 18838534-2 2008 We have established a genetically defined differentiation model in human leukemia K562 cells by conditional expression of the cyclin-dependent kinase (Cdk) inhibitor p27 (inducible by Zn(2+)) and Myc (activatable by 4-hydroxy-tamoxifen). 4'-hydroxytamoxifen 216-235 zinc ribbon domain containing 2 Homo sapiens 166-169 17520659-4 2007 Microarrays performed on E2 or 4OH-tamoxifen (4HT) treated Hs578T ERalpha and ERbeta cells revealed distinct ligand and receptor-dependent patterns of gene regulation, while the induction of ERbetacx did not alter gene expression patterns. 4'-hydroxytamoxifen 46-49 estrogen receptor 1 Homo sapiens 66-73 17520659-4 2007 Microarrays performed on E2 or 4OH-tamoxifen (4HT) treated Hs578T ERalpha and ERbeta cells revealed distinct ligand and receptor-dependent patterns of gene regulation, while the induction of ERbetacx did not alter gene expression patterns. 4'-hydroxytamoxifen 46-49 estrogen receptor 2 Homo sapiens 78-84 17428826-5 2007 Furthermore, conditional activation of the myristoylated form of Akt-Mer (myr-Akt-Mer) by 4-hydroxy-tamoxifen induced logarithmic proliferation of GS cells in the absence of GDNF for at least 5 months. 4'-hydroxytamoxifen 90-109 thymoma viral proto-oncogene 1 Mus musculus 65-68 17428826-5 2007 Furthermore, conditional activation of the myristoylated form of Akt-Mer (myr-Akt-Mer) by 4-hydroxy-tamoxifen induced logarithmic proliferation of GS cells in the absence of GDNF for at least 5 months. 4'-hydroxytamoxifen 90-109 thymoma viral proto-oncogene 1 Mus musculus 78-81 18663360-1 2008 In the presence of ERbeta, trans-hydroxytamoxifen (TOT) protects cells against 17beta-estradiol (E(2))-induced oxidative DNA damage (ODD) and this correlates with increased expression of the antioxidative enzyme quinone reductase (QR). 4'-hydroxytamoxifen 27-49 estrogen receptor 2 Homo sapiens 19-25 18072234-5 2008 Endoxifen is a metabolite with antitumor activity and affinity for the ER that is similar to 4-hydroxy-tamoxifen, but 1 that is normally present in substantially higher concentrations. 4'-hydroxytamoxifen 93-112 estrogen receptor 1 Homo sapiens 71-73 17369859-3 2007 To investigate c-Myc functions in hES cells, we expressed an inducible c-Myc fused to the hormone-binding domain of the estrogen receptor (c-MycER) protein that is activated by 4-hydroxy-tamoxifen. 4'-hydroxytamoxifen 177-196 MYC proto-oncogene, bHLH transcription factor Homo sapiens 15-20 17369859-3 2007 To investigate c-Myc functions in hES cells, we expressed an inducible c-Myc fused to the hormone-binding domain of the estrogen receptor (c-MycER) protein that is activated by 4-hydroxy-tamoxifen. 4'-hydroxytamoxifen 177-196 MYC proto-oncogene, bHLH transcription factor Homo sapiens 71-76 17369859-3 2007 To investigate c-Myc functions in hES cells, we expressed an inducible c-Myc fused to the hormone-binding domain of the estrogen receptor (c-MycER) protein that is activated by 4-hydroxy-tamoxifen. 4'-hydroxytamoxifen 177-196 estrogen receptor 1 Homo sapiens 120-137 15601818-2 2004 4-Hydroxy-tamoxifen treatment induced fak deletion in the epidermis, and suppressed chemically induced skin tumor formation. 4'-hydroxytamoxifen 0-19 PTK2 protein tyrosine kinase 2 Mus musculus 38-41 16407845-5 2006 In addition, myr-Akt-Mer fusion protein, whose enzymatic activity is controlled by 4-hydroxy-tamoxifen, also maintained the pluripotency of not only mouse but also cynomolgus monkey ES cells. 4'-hydroxytamoxifen 83-102 thymoma viral proto-oncogene 1 Mus musculus 17-20 16007218-4 2005 Here, we report the use of a membrane targeted PKBbeta, the activation of which is under the control of a 4-hydroxy-Tamoxifen-responsive estrogen-receptor (ER) ligand binding domain. 4'-hydroxytamoxifen 106-125 AKT serine/threonine kinase 2 Homo sapiens 47-54 15802376-5 2005 Both E2 and 4-hydroxy-tamoxifen were shown to regulate unique sets of endogenous genes in the U2OS-ERalpha/beta heterodimer cell line (20% and 27% of total, respectively), compared with all the genes regulated in U2OS-ER homodimer cell lines. 4'-hydroxytamoxifen 12-31 estrogen receptor 1 Homo sapiens 99-111 15647843-3 2005 To address this issue, we have established M1/STAT3ER cells, where STAT3 is selectively activated by 4-hydroxytamoxifen (4HT). 4'-hydroxytamoxifen 121-124 signal transducer and activator of transcription 3 Mus musculus 46-51 15647843-3 2005 To address this issue, we have established M1/STAT3ER cells, where STAT3 is selectively activated by 4-hydroxytamoxifen (4HT). 4'-hydroxytamoxifen 121-124 signal transducer and activator of transcription 3 Mus musculus 67-72 16835370-4 2006 Docking studies using molecular modeling of Sah 58-035 with the X-ray structure of the ER showed that Sah 58-035 fits well into the ligand binding site known for 4-hydroxy-tamoxifen. 4'-hydroxytamoxifen 162-181 acyl-CoA synthetase medium chain family member 3 Homo sapiens 44-47 16835370-4 2006 Docking studies using molecular modeling of Sah 58-035 with the X-ray structure of the ER showed that Sah 58-035 fits well into the ligand binding site known for 4-hydroxy-tamoxifen. 4'-hydroxytamoxifen 162-181 acyl-CoA synthetase medium chain family member 3 Homo sapiens 102-105 16914687-2 2006 In mice carrying the GCE (hGFAP-Cre-ER(T2)) transgene, OHT (4-hydroxy-tamoxifen) injections induced Cre recombination in astroglial cells at postnatal day 5 and allowed us to permanently tag these cells with reporter genes. 4'-hydroxytamoxifen 60-79 glial fibrillary acidic protein Homo sapiens 26-31 15941852-10 2005 Transient transfection studies show that MRF1 represses transcription by ERalpha activated by estradiol in a dose-dependent manner, as well as by the selective ER modulators 4-hydroxy-tamoxifen and raloxifene. 4'-hydroxytamoxifen 174-193 AT-rich interaction domain 5A Homo sapiens 41-45